Fortis Clinical Research Limited (FCRL) partners with pharma/biotech companies for early clinical development of New Molecular Entities (NMEs) and bioequivalence assessment of generic products for global submissions.

FCRL provides full range of services for Phase I in healthy volunteers (NMEs and generic products), Phase I in oncology, Phase IIa in patients as well as bioequivalence studies in patients.